Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $547,933.70 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the sale, the executive vice president directly owned 29,728 shares of the company’s stock, valued at $10,787,399.36. The trade was a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $359.27 on Friday. The firm has a market cap of $47.46 billion, a price-to-earnings ratio of 1,496.96 and a beta of 0.32. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The stock’s 50-day moving average price is $418.74 and its 200 day moving average price is $421.35. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55.

Analyst Upgrades and Downgrades

ALNY has been the topic of a number of research reports. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday. Piper Sandler reiterated an “overweight” rating and issued a $489.00 target price (up from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Wells Fargo & Company boosted their target price on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Royal Bank Of Canada increased their price target on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a research report on Friday, September 19th. Finally, Bank of America lowered their price objective on Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating for the company in a research report on Monday, January 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $490.96.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. LeConte Wealth Management LLC increased its holdings in Alnylam Pharmaceuticals by 14.8% in the fourth quarter. LeConte Wealth Management LLC now owns 604 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 78 shares during the last quarter. Private Advisory Group LLC increased its holdings in shares of Alnylam Pharmaceuticals by 51.9% in the 4th quarter. Private Advisory Group LLC now owns 2,155 shares of the biopharmaceutical company’s stock valued at $857,000 after acquiring an additional 736 shares during the last quarter. Northwest Wealth Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $225,000. Eastern Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $42,000. Finally, USA Financial Formulas purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $169,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.